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MaBACKGROUND Clinical trial evidence suggests poorer outcomes in blacks compared with whites when treated with
an angiotensin-converting enzyme (ACE) inhibitor–based regimen, but this has not been evaluated in clinical practice.
OBJECTIVES This study evaluated the comparative effectiveness of an ACE inhibitor–based regimen on a composite
outcome of all-cause mortality, stroke, and acute myocardial infarction (AMI) in hypertensive blacks compared with
whites.
METHODS We conducted a retrospective cohort study of 434,646 patients in a municipal health care system. Four
exposure groups (Black-ACE, Black-NoACE, White-ACE, White-NoACE) were created based on race and treatment
exposure (ACE or NoACE). Risk of the composite outcome and its components was compared across treatment groups
and race using weighted Cox proportional hazard models.
RESULTS Our analysis included 59,316 new users of ACE inhibitors, 47% of whom were black. Baseline characteristics
were comparable for all groups after inverse probability weighting adjustment. For the composite outcome, the race
treatment interaction was signiﬁcant (p ¼ 0.04); ACE use in blacks was associated with poorer cardiovascular outcomes
(ACE vs. NoACE: 8.69% vs. 7.74%; p ¼ 0.05) but not in whites (6.40% vs. 6.74%; p ¼ 0.37). Similarly, the Black-ACE
group had higher rates of AMI (0.46% vs. 0.26%; p ¼ 0.04), stroke (2.43% vs. 1.93%; p ¼ 0.05), and congestive heart
failure (3.75% vs. 2.25%; p < 0.0001) than the Black-NoACE group. However, the Black-ACE group was no more likely to
develop adverse effects than the White-ACE group.
CONCLUSIONS ACE inhibitor–based therapy was associated with poorer cardiovascular outcomes in hypertensive
blacks but not in whites. These ﬁndings conﬁrm clinical trial evidence that hypertensive blacks have poorer outcomes
than whites when treated with an ACE inhibitor–based regimen. (J Am Coll Cardiol 2015;66:1224–33)
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1225AB BR E V I A T I O N S
AND ACRONYM S
ACE = angiotensin-converting
enzyme
AMI = acute myocardial
infarction
BP = blood pressure
CCB = calcium-channel blocker
CI = conﬁdence intervalI n the United States, blacks have dispropor-tionately higher hypertension-related morbidityand mortality than other racial/ethnic groups
(1); plus, hypertension explains much of the variance
in mortality between blacks and whites (2). Despite
the higher rates of cardiovascular disease (CVD),
blacks are underrepresented in randomized,
controlled trials of therapeutic medications, with a
participation rate of <30% in heart failure trials (3).SEE PAGE 1234 CV = cardiovascular
CVD = cardiovascular disease
CHF = congestive heart failure
EHRs = electronic health
records
HHC = Health and Hospital
Corporation
HR = hazard ratio
ICD-9 = International
Classiﬁcation of Diseases-
9th edition
IPTW = inverse probability of
treatment weights
= systolic blood pressureAngiotensin-converting enzyme (ACE) inhibitors
are commonly prescribed for treatment of hyperten-
sion; however, despite their proven efﬁcacy on blood
pressure (BP) reduction (4), their relative effective-
ness on cardiovascular (CV) outcomes in hypertensive
blacks remains uncertain (5). Clinical trial evidence
suggests that ACE inhibitors may not provide the
same beneﬁts in blacks compared with whites and, in
fact, may cause harm (6–9). One retrospective study
of 2,225 patients found a 19% rate of ACE inhibitor
discontinuation due to adverse events (10). Among
15,100 blacks enrolled in ALLHAT (Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart
Attack Trial), those treated with ACE inhibitors had
poorer CV outcomes and lesser decreases in BP than
those randomized to a thiazide-type diuretic, chlor-
thalidone (5,9,11). The SOLVD (Study Of Left Ven-
tricular Dysfunction) trial found a signiﬁcant
reduction in hospitalizations for congestive heart
failure (CHF) among whites on an ACE inhibitor, but
no such reduction was found in blacks (12). Despite
the relatively lower clinical effectiveness of ACE in-
hibitor–based treatment in hypertensive blacks
compared with whites enrolled in clinical trials, there
are limited data on the comparative effectiveness of
ACE inhibitor–based regimens on important health
outcomes in hypertensive blacks compared with
whites in clinical practice settings.
In this study, we evaluated racial differences in
the comparative effectiveness and safety of ACE in-
hibitor–based regimens in hypertensive blacks com-
pared with whites, using a longitudinal dataset derived
from electronic health records (EHRs) of hypertensive
patients who received care within New York City’s
Health and Hospital Corporation (HHC). We hypothe-
sized that an ACE inhibitor–based regimen would be
less effective and lead to higher rates of serious adverse
effects (hyperkalemia) in blacks compared with whites.
METHODS
STUDY DESIGN, SETTING, AND POPULATION. This
study was conducted in New York City’s HHC, whichoversees the city’s public health care system
in all 5 boroughs. The corporation consists of
11 acute care hospitals, 6 diagnostic and
treatment centers, 4 long-term care facilities,
a certiﬁed home health care agency, and more
than 80 community health clinics. It is the
largest municipal hospital and health care
system in the country: a $5.4 billion public
beneﬁt corporation that serves 1.8 million
New Yorkers. HHC provides care for approx-
imately 20% of all general hospital discharges
and more than 30% of all emergency depart-
ment and hospital-based clinic visits in New
York City. Approximately 35% of patients
seen in the HHC system are black and 7% are
white.
Using a retrospective cohort design, we
extracted EHR data (BP measurements,
weight, prescription reﬁlls, laboratory test
results, clinical diagnoses, encounter di-
agnoses for outpatient visits, diagnostic im-
aging tests, and health care utilization) from
HHC’s clinical data warehouse. The study
population was comprised of adult hypertensive pa-
tients (age $18 years), who received care between
January 1, 2004, and December 31, 2009, and who met
the following criteria: hypertension diagnosis (based
on hypertension International Classiﬁcation of Dis-
eases-9th edition [ICD-9] code on $2 clinic visits)
and prescribed an ACE inhibitor, b-blocker, thiazide-
type diuretic, or calcium-channel blocker (CCB) for
at least 6 months after their ﬁrst date of entry into
the HHC system. We excluded patients who were
not self-identiﬁed as African American, black, or
Caucasian, and those with a prior history of nonfatal
acute myocardial infarction (AMI), nonfatal stroke,
or CHF, because these medications are compelling
indications for ACE inhibitor use. The study was
approved by the institutional review boards of both
the New York University School of Medicine and
the HHC.
STUDY MEASURES AND OUTCOMES. The primary
outcome was a composite of all-cause mortality,
nonfatal AMI, and nonfatal stroke. Secondary out-
comes included individual components of the com-
posite outcome, CHF, kidney failure, and safety
outcomes, which included severe side effects (hyper-
kalemia, deﬁned as serum potassium >5.5 mEq/l, and
hypokalemia, deﬁned as a serum potassium of 2 to
3.5 mEq/l). All outcomes were extracted from the
EHR using the corresponding ICD-9 codes from the
patient’s problem list and laboratory values. For these
analyses, we followed patients for up to 2,000 days,
with an average follow-up time of 4.5 years. For each
SBP
FIGURE 1 Relationship of Antihypertensive Medication Exposures to
Cardiovascular Outcomes
Outcomes eligible
for analysis
Minimum 6
months pass
before exposure
6 months
Time
Patients
enter
system
Patient starts
ACE inhibitor / β-blockers /
thiazide-type diuretics /
calcium channel blockers
(exposure)
This ﬁgure depicts the timeframe for study eligibility for adult hypertensive patients
(age$18 years), who received care between January 1, 2004, and December 31, 2009, and
who met the following criteria: hypertension diagnosis (based on hypertension ICD-9 code
on at least 2 clinic visits); and prescribed an ACE inhibitor, b-blockers, thiazide-type
diuretics, or calcium-channel blockers for at least 6 months after their ﬁrst date of entry
into the HHC system. Outcomes through December 31, 2009 were eligible for analysis.
ACE ¼ angiotensin-converting enzyme; HHC ¼ Health and Hospital Corporation;
ICD-9 ¼ International Classiﬁcation of Diseases-9th edition.
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to-event, starting from the index date and ending
when the outcome was observed or when the study
ended (resulting in right censoring). A patient’s index
date was based on the start of a drug regimen (either
ACE or non-ACE regimen), and was required to be at
least 180 days after the patient’s entry into the study.
A patient’s exposure status to prescribed antihyper-
tensive medications was assessed for the entire
study period (Figure 1).
In the EHR, patient race is typically recorded based
on self-reporting, the gold standard for such classiﬁ-
cation (13,14). Race data were collapsed into African
American or black, Caucasian or white, Asian, Native
American/Alaskan, and Native Hawaiian/Other Paciﬁc
Islander, following the U.S. Ofﬁce of Management and
Budget classiﬁcations, with only blacks and whites
included in the analyses.
We identiﬁed new users (an inception cohort)
for each antihypertensive medication, to prevent
“healthy user” effects that result from studying
patients who are not treatment naïve (15). A 6-month
period after the ﬁrst date of entry into the EHR was
required to ensure that patients were new users of the
relevant medication for both ACE and non-ACE
groups. Patients were grouped based on the ﬁrst
antihypertensive medication they were prescribed.Patients whose ﬁrst antihypertensive medication was
an ACE inhibitor were categorized as the ACE group
and those whose ﬁrst antihypertensive medications
were a b-blocker, thiazide-type diuretic, or a CCB
were categorized as the NoACE group. In the NoACE
group, 46.6% were on b-blockers, 51% were taking
thiazide-type diuretics, and 33.6% were on CCBs. For
the ACE group, during the course of follow-up, 4.6%
were also on b-blockers, 8.4% were taking thiazide-
type diuretics, and 19.8% were on a CCB.
We included laboratory tests, clinical diagnoses, or
encounter diagnosis-derived events that occurred at
least 28 days after the prescription-documented time
that the patient was on that antihypertensive medi-
cation. Adverse events were attributed to the medi-
cation only after its initiation. If an event occurred
multiple times (e.g., hyperkalemia), we included only
the ﬁrst occurrence.
COVARIATES USED FOR RISK ADJUSTMENT. We
considered the following variables to adjust for
potential confounding or as potential effect modi-
ﬁers: age, sex, calendar year of entry into the system,
number of clinic visits in the previous year, baseline
systolic and diastolic BP, and comorbidity using the
Charlson Comorbidity Index, which includes diabetes
mellitus, renal disease, chronic pulmonary disease,
connective tissue disease, cerebrovascular accident,
liver disease, and cancer. The Charlson Comorbidity
Index is a well-validated tool that has been used in
clinical trials to adjust for the confounding effect of
comorbid conditions on outcomes and mortality (16).
We also included baseline creatinine values, choles-
terol values, and potassium; medications that can
cause hyperkalemia or hypokalemia (e.g., nonste-
roidal anti-inﬂammatory drugs, statin); and other
antihypertensive medications (e.g., angiotensin re-
ceptor blocker, CCB) as covariates.
STATISTICAL ANALYSIS. Because patients were not
randomly assigned to treatment in this study, we
applied inverse probability of treatment weights
(IPTW) (17,18) to our analyses. This ensured that all
treatment and nontreatment groups were balanced
across potentially confounding covariates and mini-
mized bias due to confounding by indication (19). The
weights were calculated by dividing the probability of
group membership by the probability of group mem-
bership conditional on the covariates (i.e., the pro-
pensity score). We estimated the probabilities using
multinomial logistic regression models. The covar-
iates in the propensity score model included risk
factors that were considered potential confounders of
the association of race and hypertension treatment
group (ACE vs. NoACE) with the composite outcome.
FIGURE 2 Patient Flow Chart
Hypertensive patients
meeting study inclusion criteria
N = 434,646
N = 359,499
N = 275,217
N = 76,546
Final Sample
N = 59,316
ACE: 28,952
No-ACE: 30,364
Blacks: 28,087
Whites: 31,229
Exclude: (N = 75,147)
Age <18 or >90 years
Not African American
/Black or White
Missing year of entry
Missing follow-up date
Exclude: (N = 84,282)
1st ACE / β-blockers / thiazide /
CCB prescription <180 days of
entry into the system
Exclude: (N = 198,671)
Received the 1st ACE after 180
days (with no refills)
Multiple duplicate patient visits
Exclude: (N = 17,230)
History of CHF, AMI or
stroke
On ARB
Deceased patients
Patients with negative TTE
outcomes - the last follow-
up date is smaller than the
index date
IPTW >10
The process used to select the ﬁnal study sample for analyses. At baseline, 434,646
hypertensive patients met the initial study criteria, of which 359,499 met the second
inclusion criteria including age and race. Of this, 275,217 were on 1 of the 4 study anti-
hypertensive medications for at least 6 months after their ﬁrst date of entry into the HHC
system. We eliminated patients who were prescribed ACE only once with no reﬁll, and
those with multiple duplicate visits, leaving a sample size of 76,546. Our ﬁnal sample
of 59,316 excluded additional patients including those with study outcomes of interest.
ACE ¼ angiotensin-converting enzyme; AMI ¼ acute myocardial infarction; ARB ¼ angio-
tensin receptor blocker; CCB ¼ calcium-channel blocker; CHF ¼ congestive heart failure;
IPTW ¼ inverse probability of treatment weights; TTE ¼ transthoracic echocardiography.
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founders after applying the weights to conﬁrm that
the groups were balanced adequately.
For each primary and secondary outcome, we
estimated IPTW-weighted incident rates for all 4 race/
treatment groups. We used weighted Cox propor-
tional hazard models to conduct a within-race com-
parison of hypertension treatment regimens (ACE vs.
NoACE). The Cox regression used days as the unit of
time. For each adverse event, we estimated a hazard
ratio (HR) for each group (blacks and whites),
providing a measure of risk for blacks and whites on
ACE inhibitors compared with blacks and whites
receiving other types of antihypertensive medica-
tions, respectively. Finally, we compared the HRs for
blacks and whites using ratios of HRs. We reported all
ratios along with their 95% conﬁdence intervals (CIs).
Analyses were conducted using SAS software, version
9.3 (SAS Institute, Cary, North Carolina).
RESULTS
A total of 434,646 patients met inclusion criteria
(Figure 2); of these, 76,546 were prescribed medica-
tions from 1 of the 4 antihypertensive drug classes
(ACE inhibitor, b-blocker, CCB, or thiazide-type
diuretic) during the study period. Patients were
excluded for a prior diagnosis of nonfatal AMI,
nonfatal stroke, CHF, or kidney failure before pre-
scription, ﬁrst antihypertensive prescription <180
days of entry into the system, prescriptions with no
reﬁlls, multiple visits for the same event, dying
before prescription date, having a follow-up date
earlier than the index date, and having an IPTW
of >10. This left a ﬁnal sample of 59,316 patients
(47% black). The baseline characteristics of all 4 study
groups (Black-ACE, Black-NoACE, White-ACE, and
White-NoACE) before IPTW matching are summa-
rized in Tables 1 and 2. There were signiﬁcant differ-
ences between the 4 groups. However, after IPTW
matching, the baseline characteristics were well-
matched for most variables (nearly all of the stan-
dardized differences were <10%), with the exception
of very low and high-density lipoprotein and triglyc-
eride levels.
As seen in the results of the primary and secondary
analyses (Table 3), incident rates for CV outcomes
were higher for the Black-ACE group compared with
the Black-NoACE group for most of the outcomes.
Speciﬁcally, the Black-ACE group had higher rates of
AMI (0.46% vs. 0.26%), stroke (2.43% vs. 1.93%), and
CHF (3.75% vs. 2.25%) than the Black-NoACE group.
However, the HRs indicate that these differences
were statistically signiﬁcant only for AMI (HR: 1.76;95% CI: 1.02 to 3.01) and CHF (HR: 1.64; 95% CI: 1.34
to 2.02). The differences in incident rates of CV out-
comes for the White-ACE group versus the White-
NoACE group did not have any apparent pattern.
All-cause mortality was the only outcome for whites
with a signiﬁcant difference (HR: 0.87; 95% CI: 0.76 to
1.00), suggesting that the ACE-based regimen may be
protective with respect to death for white patients.
For all other outcomes, there were no apparent dif-
ferences between ACE and NoACE groups among
whites.
As shown in Table 2, for the composite outcome,
ACE inhibitor use was associated with poorer out-
comes in blacks (ACE vs. NoACE; 8.7% vs. 7.7%; p ¼
0.05) but not in whites (ACE vs. NoACE; 6.40% vs.
6.74%; p ¼ 0.37). A comparison of the HRs of blacks
versus whites indicates that the relative risk for the
TABLE 1 Baseline Characteristics Before Inverse Probability Weights Adjustment
IPW Unadjusted
White-NoACE (1)
(n ¼ 15,214)
White-ACE (2)
(n ¼ 16,015)
Black-NoACE (3)
(n ¼ 15,150)
Black-ACE (4)
(n ¼ 12,937)
Absolute Differences
Between Groups*
1-2 1-3 1-4
Age, yrs 51.8  13.99 52.90  13.14 49.10  13.51 50.91  12.95 1.52 2.28 0.47
Female 63.2 55.9 65.8 58.2 7.3 2.6 5
BMI, kg/m2 33.03  11.83 32.85  11.09 32.79  11.00 32.45  10.98 0.18 0.24 0.58
Systolic BP, mm Hg 140.81  20.07 139.37  20.04 148.40  21.03 144.34  21.35 1.44 7.59 3.53
Diastolic BP, mm Hg 81.44  12.11 80.19  11.87 84.98  12.96 82.53  13.09 1.25 3.54 1.09
Pulse 78.63  13.79 77.98  13.30 80.17  13.83 80.22  14.21 0.65 1.54 1.59
Times hospitalized within 1 year, n 0.42  0.88 0.48  0.91 0.40  0.86 0.57  1.06 0.06 0.02 0.15
Days hospitalized within 1 year, n 2.48  9.76 2.55  9.65 2.83  16.33 3.69  16.35 0.07 0.35 1.21
Clinic visits within 1 year, n 10.68  17.00 11.30  17.21 9.84  17.39 10.70  20.07 0.62 0.84 0.02
Has insurance 85.6 85.3 79.6 80.9 0.3 6.0 4.7
Number of additional antihypertensive agents
0 87.3 86.3 90.2 83.6 1.0 2.9 3.7
1 10.4 12.3 7.9 15.0 1.9 2.5 4.6
2 1.9 1.0 1.5 0.9 0.9 0.4 1.0
$3 0.3 0.4 0.3 0.5 0.1 0.0 0.2
Comorbidities
Atrial ﬁbrillation 1.6 1.9 0.9 1.4 0.3 0.7 0.2
AMI 0.0 0.0 0.0 0.0
Angina 1.5 2.1 0.8 1.4 0.6 0.7 0.1
Cancer 3.4 2.9 4.4 3.7 0.5 1.0 0.3
CAD 3.1 6.1 1.7 3.9 3.0 1.4 0.8
Cardiac dysrhythmias 3.4 3.7 2.5 3.1 0.3 0.9 0.3
CHF 0.0 0.0 0.0 0.0
Chronic pulmonary disease 0.2 0.2 0.2 0.2 0.0 0.0 0.0
Connective tissue disease 0.7 0.8 0.7 1.1 0.1 0.0 0.4
Cerebrovascular accident 0.0 0.0 0.0 0.0
Diabetes 13.5 43.7 14.4 43.6 30.2 0.9 30.1
Diseases of mitral valve 0.1 0.1 0.1 0.1 0.0 0.0 0.0
Endocardial disease 0.0 0.1 0.0 0.0 0.1 0.0 0.0
Hemorrhagic stroke 0.0 0.0 0.0 0.0
Hypertensive kidney disease 0.1 0.1 0.1 0.2 0.0 0.0 0.1
Ischemic stroke 0.0 0.0 0.0 0.0
Renal disease 0.9 0.5 1.7 2.1 0.4 0.8 1.2
Charlson score category
0 82.1 55.5 80.3 53.7 26.6 1.8 28.4
1-3 17.5 44.2 19.2 45.9 26.7 1.7 28.4
$4 0.5 0.3 0.5 0.4 0.2 0.0 0.1
Laboratory measures
BUN, mg/dl 15.72  7.46 16.36  6.70 14.88  7.73 15.50  7.76 0.64 0.84 0.22
LDL, mg/dl 113.24  35.65 110.27  36.67 113.70  37.00 111.03  38.83 2.97 0.46 2.21
HDL, mg/dl 50.83  15.01 49.06  14.30 55.54  16.67 53.90  16.89 1.77 4.71 3.07
Creatinine, mg/dl 0.90  0.55 0.89  0.36 1.03  0.88 1.06  0.89 0.01 0.13 0.01
GFR, ml/min/1.73 m2 66.09  15.06 64.15  13.89 65.42  16.18 62.79  15.54 1.94 0.67 3.30
HbA1c, % 6.60  1.69 7.86  2.56 6.73  1.76 8.00  2.59 1.26 0.13 1.40
Triglycerides, mg/dl 146.63  90.85 161.63  102.71 113.42  69.88 121.16  79.25 15.00 33.21 25.47
Potassium, mEq/l 4.27  0.48 4.31  0.45 4.15  0.47 4.19  0.47 0.04 0.12 0.08
Sodium, mEq/l 139.59  2.87 139.38  2.98 139.65  2.96 139.27  3.40 0.21 0.06 0.32
VLDL, mg/dl 30.16  18.51 32.57  21.11 23.22  13.57 24.16  14.60 2.41 6.94 6.00
Values are mean  SD or % unless otherwise indicated. *Difference between group means and proportions.
ACE ¼ angiotensin-converting enzyme; AMI ¼ acute myocardial infarction; BMI ¼ body mass index; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; CAD ¼ coronary artery
disease; CHF ¼ congestive heart failure; GFR ¼ glomerular ﬁltration rate; HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density lipoprotein; IPW ¼ inverse probability weights;
LDL ¼ low-density lipoprotein; VLDL ¼ very low-density lipoprotein.
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TABLE 2 Baseline Characteristics After IPW Adjustment
IPW Adjusted
White-NoACE (1)
(n ¼ 15,214)
White-ACE (2)
(n ¼ 16,015)
Black-NoACE (3)
(n ¼ 15,150)
Black-ACE (4)
(n ¼ 12,937)
Absolute Differences
Between Groups*
1-2 1-3 1-4
Age, yrs 51.48  12.97 51.32  12.19 51.07  13.30 50.99  12.86 0.16 0.41 0.49
Female 59.6 58.0 60.4 59.7 1.6 0.8 0.1
BMI, kg/m2 32.88  10.62 32.72  10.23 32.65  10.74 32.60  11.08 0.16 0.23 0.28
Systolic BP, mm Hg 142.44  19.64 141.60  19.12 143.94  20.28 143.75  21.06 0.84 1.50 1.31
Diastolic BP, mm Hg 81.98  11.88 81.67  11.65 82.66  12.36 82.62  12.97 0.31 0.68 0.64
Pulse 78.86  13.21 78.81  12.59 79.65  13.32 79.34  14.02 0.05 0.79 0.48
Times hospitalized within 1 year, n 0.49  0.87 0.49  0.86 0.49  0.90 0.48  0.95 0.00 0.00 0.01
Days hospitalized within 1 year, n 2.77  9.76 2.78  10.21 3.05  12.19 2.90  13.05 0.01 0.28 0.13
Clinic visits within 1 year, n 11.28  17.76 11.25  18.42 11.12  19.84 11.07  20.61 0.03 0.16 0.21
Has insurance 86.9 85.3 84.0 83.2 1.6 2.9 3.7
Number of additional antihypertensive agents
0 85.0 86.4 86.4 86.4 1.4 1.4 1.4
1 12.8 11.6 11.7 11.5 1.2 1.1 1.3
2 1.8 1.5 1.4 1.7 0.3 0.4 0.1
$3 0.4 0.4 0.5 0.4 0.0 0.1 0.0
Comorbidities
Atrial ﬁbrillation 1.8 1.6 1.4 1.6 0.2 0.4 0.2
AMI 0.0 0.0 0.0 0.0
Angina 1.7 1.6 1.4 1.4 0.1 0.3 0.3
Cancer 3.4 3.4 3.9 3.6 0.0 0.5 0.2
CAD 4.5 4.3 3.2 3.9 0.2 1.3 0.6
Cardiac dysrhythmias 3.7 3.3 3.3 3.2 0.4 0.4 0.5
CHF 0.0 0.0 0.0 0.0
Chronic pulmonary disease 0.2 0.2 0.2 0.2 0.0 0.0 0.0
Connective tissue disease 0.8 0.9 0.9 0.9 0.1 0.1 0.1
Cerebrovascular accident 0.0 0.0 0.0 0.0
Diabetes 27.6 30.8 26.8 29.2 3.2 0.8 1.6
Diseases of mitral valve 0.1 0.1 0.1 0.2 0.0 0.0 0.1
Endocardial disease 0.0 0.1 0.0 0.0 0.1 0.0 0.0
Hemorrhagic stroke 0.0 0.0 0.0 0.0
Hypertensive kidney disease 0.1 0.1 0.1 0.3 0.0 0.0 0.2
Ischemic stroke 0.0 0.0 0.0 0.0
Renal disease 1.3 1.1 1.9 1.7 0.2 0.6 0.4
Charlson score category
0 70.1 65.9 69.8 67.0 4.2 0.3 3.1
1-3 29.3 33.7 29.4 32.4 4.4 0.1 3.1
$4 0.6 0.4 0.7 0.5 0.4 0.1 0.1
Laboratory measures
BUN, mg/dl 16.14  8.01 15.74  15.85 6.31  7.85 16.06  7.99 8.13 0.29 9.83
LDL, mg/dl 110.94  34.62 111.62  32.61 111.97  37.81 110.93  37.01 0.68 1.03 0.01
HDL, mg/dl 50.99  15.13 50.96  14.04 52.78  15.93 52.02  15.53 0.03 1.79 1.03
Creatinine, mg/dl 0.97  0.78 0.91  0.48 1.02  0.67 1.03  0.69 0.06 0.05 0.06
GFR, ml/min/1.73 m2 64.21  15.16 64.86  13.23 64.01  16.71 63.99  16.54 0.65 0.2 0.22
HbA1c, % 7.38  2.60 7.49  2.03 7.29  2.21 7.43  2.04 0.11 0.09 0.05
Triglycerides, mg/dl 143.13  85.45 145.76  79.74 130.19  87.96 139.44  103.35 2.63 13.11 3.69
Potassium, mEq/l 4.26  0.46 4.26  0.42 4.22  0.47 4.23  0.51 0.00 0.04 0.03
Sodium, mEq/l 139.41  2.89 139.41  2.72 139.57  2.91 139.44  3.18 0.00 0.16 0.03
VLDL, mg/dl 30.56  22.01 30.22  18.54 24.75  12.41 25.82  13.63 0.34 5.81 4.74
Values are mean  SD or % unless otherwise indicated. *Difference between group means and proportions.
IPW ¼ inverse probability weights; other abbreviations as in Table 1.
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TABLE 3 Incident Rates and HRs for Black and White Patients and ACE Inhibitor Use
Outcomes
Blacks: Incident Rates Over
Study Duration
Whites: Incident Rates Over
Study Duration Ratio of HRs
NoACE ACE HR (95% CI) NoACE ACE HR (95% CI) (Blacks vs. Whites)
Composite of AMI, stroke, and all-cause mortality 7.7 8.7 1.11 (0.99–1.25) 6.7 6.4 0.94 (0.84–1.06) 1.18 (1.00–1.40)*
AMI 0.3 0.5 1.76 (1.02–3.01)* 0.3 0.5 1.43 (0.86–2.37) 1.23 (0.59–2.58)
Stroke 1.9 2.4 1.25 (0.99–1.57) 1.9 2.0 1.02 (0.80–1.29) 1.22 (0.88–1.71)
All-cause mortality 6.0 6.2 1.02 (0.89–1.18) 4.9 4.4 0.87 (0.76–1.00)* 1.17 (0.96–1.42)
Hyperkalemia 0.9 1.1 1.21 (0.88–1.68) 0.8 0.8 0.92 (0.61–1.39) 1.32 (0.78–2.23)
Hypokalemia 0.2 0.2 0.68 (0.35–1.31) 0.2 0.2 0.90 (0.26–3.07) 0.75 (0.19–3.04)
Renal disease 0.2 0.2 1.15 (0.63–2.12) 0.3 0.2 0.56 (0.26–1.18) 2.06 (0.79–5.42)
CHF 2.3 3.8 1.64 (1.34–2.02)† 2.4 2.7 1.12 (0.93–1.35) 1.47 (1.11–1.94)†
Values are %. *p < 0.05. †p < 0.01.
HR ¼ hazard ratio; other abbreviations as in Table 1.
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NoACE was higher than the relative risk for whites
on an ACE inhibitor compared with NoACE. The test
for race treatment interaction was signiﬁcant for the
composite outcome with blacks having a higher event
rate than whites (blacks vs. whites; HR: 1.18; 95% CI:
1.00 to 1.40; p < 0.05). A summary of the overall re-
sults is depicted in the Central Illustration. However,
the Black-ACE group was no more likely to develop
adverse effects (i.e., hyperkalemia, hypokalemia)
than the White-ACE group.
Because clinical trial results suggest that ACE-
inhibitor treatment leads to a smaller decrease in
systolic blood pressure (SBP) in blacks compared with
whites (9,12), we adjusted for the black–white differ-
ences in achieved SBP in all analysis models. For this
purpose, we deﬁned the adjusted achieved SBP as the
average SBP for each patient closest to the study
endpoint. Our results show that blacks have higher
achieved SBP levels (137.9  20.2 mm Hg) compared
with whites (135.1  19.5 mm Hg). After adjustment
for black–white differences in achieved SBP, the pri-
mary outcomes in the study remained essentially
unchanged.
DISCUSSION
This is the ﬁrst study to use a comparative effective-
ness research design for a longitudinal dataset of
hypertensive patients who receive care in a municipal
health care system to evaluate racial differences in
the effectiveness and safety of ACE inhibitor–based
regimen in blacks compared with whites. Our ﬁndings
demonstrate that hypertensive blacks on an ACE
inhibitor–based regimen had higher rates of events
and were at higher risk of the composite outcome of
all-cause mortality, nonfatal AMI, or nonfatal stroke
than whites on an ACE inhibitor–based regimen.Additionally, blacks on ACE inhibitors were more
likely to develop CHF compared with whites. There
were no differences in rates of serious adverse effects
for both groups.
Our ﬁndings support clinical trial evidence from
ALLHAT, in which blacks on the ACE inhibitor lisi-
nopril had a 19% higher risk of combined CVD, 30%
higher risk of heart failure, and 40% higher risk of
stroke than those randomized to a thiazide-type
diuretic (chlorthalidone) (9). The magnitude of the
risk of combined CVD and CHF noted in ALLHAT was
similar to that in our study. However, with respect to
stroke, although blacks on an ACE inhibitor–based
regimen had a 25% higher risk of stroke than their
counterparts not on ACE inhibitors, in our study, this
ﬁnding did not reach statistical signiﬁcance.
Although the reasons for the noted disparities in
clinical effectiveness of ACE inhibitor–based regi-
mens between blacks and whites remain unclear, the
prevailing theory is that blacks are less responsive to
ACE inhibitors compared with whites (12), particu-
larly with respect to BP reduction. For example, in
ALLHAT, blacks had higher average follow-up BP
than whites (9). The time-dependent BP adjustment
did not alter differences in outcome for the lisinopril
versus chlorthalidone comparison among blacks in
ALLHAT (9). Similarly, in our study, we controlled for
baseline differences in BP between both groups using
propensity score matching, and we also adjusted for
the noted black–white difference in achieved SBP in
the outcomes model; as such, we cannot attribute the
noted differences to relatively less responsiveness
(with respect to SBP reduction) of blacks to ACE
inhibitors. Another reason may be that blacks are
inherently at greater risk for CV events, such as
stroke, for the same level of increased SBP. For
example, a recent analysis of the REGARDS (Reasons
for Geographic And Racial Differences in Stroke)
CENTRAL ILLUSTRATION HRs of Effects of ACE Inhibitor–Based
Therapy Versus Non–ACE-Based Therapy on CV Outcomes in
Patients With Hypertension
Ogedegbe, G. et al. J Am Coll Cardiol. 2015; 66(11):1224–33.
ACE inhibitor use was associated with poorer outcomes in blacks than in whites (8.7% vs.
6.40%). A comparison of the HRs of blacks versus whites indicates that the relative risk
for the composite outcome for blacks on ACE compared with NoACE was higher than
the relative risk for whites on ACE compared with NoACE. The test for race treatment
interaction was signiﬁcant for the composite outcome with blacks having a higher event
rate than whites (blacks versus whites: HR: 1.18; 95% CI: 1.00 to 1.40; p <0.05). Black-
ACE group experienced higher rates of AMI, stroke, and CHF compared with white-ACE
group. Abbreviations: ACE ¼ angiotensin-converting enzyme; CI ¼ conﬁdence interval;
CV ¼ cardiovascular; HR ¼ hazard ratio; MI ¼ myocardial infarction.
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blacks suffered 3 times more strokes than whites (20).
The use of propensity score matching of clinical
characteristics of all 4 exposure groups in our study
allowed us to control for the inherent differences in
CVD risk due to race (being black) in addition to
controlling for baseline SBP. Thus, we could not
ascertain that our ﬁndings are driven by the inherent
risk of CVD attributed to being black. Our ﬁndings, in
addition to those of ALLHAT (9), make a solid case for
the comparatively lesser beneﬁcial effects of ACE
inhibitors in prevention of CV outcomes in hyper-
tensive black patients compared with their white
counterparts. These ﬁndings lend credence to the
2014 evidence-based guideline for the management
of hypertension in U.S. adults (21), in which initiation
of antihypertensive therapy in black patients pre-
cludes the use of ACE inhibitors.
In addition to providing real-world, practice-based
clinical evidence on the role of ACE inhibitors in
treating hypertension in blacks, ﬁndings from this
study have the following strengths. First, this study
includes the largest number of blacks in a compara-
tive effectiveness research study that we are aware
of; such a large sample size with practice-based clin-
ical care data are not usually observed in randomized
trials, and the complementary statistical models
applied ensure our ﬁndings’ internal validity. Second,
the racial diversity of the study population in the
New York City HHC clinical data warehouse makes
inferences drawn from our ﬁndings generalizable to
hypertensive black patients who receive care in
municipal health care settings across the United
States. Third, access to care or health insurance
coverage does not pose a barrier to patients who
receive care within the HHC system, thus minimizing
the bias from lack of access to care. Finally, time
trends in treatment of hypertension and adoption
of treatment guidelines were likely to have been
consistent over the study period for which the data
were collected for both racial groups.
STUDY LIMITATIONS. We should note the following
potential sources of bias that are inherent to analysis
of nonrandomized studies and the use of a retro-
spective cohort study design of ambulatory and
hospital databases that may create challenges in
establishing causal relationships (22). First is the
issue of confounding by indication (19); we employed
propensity scores and an incident cohort of patients
using IPTW to address this issue in our data analysis.
Propensity score models are useful to mitigate selec-
tion bias in comparative effectiveness studies using
observational data (23). Although we included a wide
range of potential confounders in the propensity
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Black patients with hyper-
tension respond less favorably to ACE inhibitors than
white patients as reﬂected in BP-lowering and clinical
CV outcomes.
TRANSLATIONAL OUTLOOK: Additional research
is needed to understand the mechanisms underlying
the disparate clinical effectiveness of ACE-inhibitor
medication between blacks and whites.
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confounding could bias the results. Second is the
uncertainty about the quality of medical record data,
given that such databases are not designed for
research purposes (24). To mitigate this problem, we
conducted quality assurance testing with a random
sample of 200 participant charts, focusing on major
outcome variables. Data from the charts were
compared against those obtained from the EHRs and
90% of the data were valid. Finally, our conclusions
are somewhat limited because prescription reﬁll data
were based on EHR reporting, which makes it difﬁcult
to conﬁrm whether or not the prescription was ﬁlled.
For conﬁrmation of prescription reﬁll, we will have to
match these data to a pharmaceutical database, to
which we do not have access. This disconnect makes
it difﬁcult for us to ascertain the differences in
medication adherence between blacks and whites or
even have a sense of the overall rate of medication
adherence within the health care system. Similarly,
the mortality data we used may be incomplete, given
that some patients may have died outside the hospital
system, which can lead to underestimation of mor-
tality rates reported for the various groups.
CONCLUSIONS
ACE inhibitor–based therapy was associated with
poorer CV outcomes in hypertensive blacks but notin whites. These ﬁndings conﬁrm clinical trial evi-
dence that hypertensive black patients have poorer
outcomes than whites when treated with an ACE
inhibitor–based regimen.
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